Skip to search formSkip to main contentSkip to account menu

CDX-110

Known as: CDX 110, CDX110 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
2021 Background: Unlike conventional therapies for GBM, immunologic targeting of tumor-specific gene mutations allows precise… 
2016
2016
2034 Background: TRegs are increased in patients with GBM and constitutively express the high affinity interleukin-2 receptor (IL… 
2014
2014
BACKGROUND: EGFRvIII, a constitutively active tumorigenic EGFR deletion mutation, is linked to poor long-term survival. The… 
2013
2013
e13023 Background: Several strategies have been recently developed to target EGFRvIII in Glioblastoma Multiforme (GBM), including… 
2012
2012
TPS2103 Background: EGFRvIII is a constitutively active tumorigenic deletion mutation of EGFR. It is expressed in ~30% of primary… 
2010
2010
2014 Background: EGFRvIII is a constitutively activated mutation of EGFR, not expressed in normal tissues but expressed in GBM… 
2010
2010
Celldex Therapeutics is developing rindopepimut (CDX-110), a 14-mer injectable peptide vaccine for the potential treatment of… 
2008
2008
2011 Background: Conventional therapies for GBM fail to target tumor cells exclusively. Immunologic targeting of tumor- specific… 
2008
2008
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2008
2008
Gateways to clinical trials is a guide to the most recent trials in current literature and congresses. The data in the following…